Mint Pharmaceuticals Donates Hydroxychloroquine to St. Joseph's Healthcare Hamilton Clinical Study for Prevention of COVID-19 Amongst Front Line Healthcare Workers and Early Treatment of Mild Cases
MISSISSAUGA, ON, April 20, 2020 /CNW/ - Mint Pharmaceuticals, one of Canada's leading generic pharmaceutical companies, is donating Hydroxychloroquine to support a critical and timely St. Joseph's Healthcare Hamilton study being led at this site by Dr. Zain Chagla, Associate Professor of Medicine at McMaster University.
The randomized placebo-controlled study, conducted by The Research Institute of St. Joseph's Hospital, at St. Joseph's Healthcare Hamilton, evaluates the use hydroxychloroquine for the prevention of COVID-19 amongst exposed healthcare workers and household contacts, as well as evaluates the use of hydroxychloroquine for the early treatment of mild cases. The study uses an online platform for enrollment, so that every adult patient who meets study criteria in Ontario, independent of location, may be able to register. Results will be pooled by with other centers running the same study across North America.
"There has been a significant amount of off-label use of hydroxychloroquine globally in the COVID-19 pandemic, and very little of it has been informed by evidence. We hope this randomized study, regardless of the results, helps to provide more robust clinical evidence to inform decision making, something that is much needed for this pandemic" said Dr. Zain Chagla, Associate Professor of Medicine at McMaster University and co-investigator for the study. "We appreciate Mint Pharmaceuticals' commitment to this very timely study."
"All of us at Mint are proud to support this important research. At a time where demand for this and other critical medications has spiked due to this global pandemic, the primary objective of our company is to continue to provide Canadians with reliable access to these medications." said Jaiveer Singh, CEO of Mint Pharmaceuticals Inc.
"As Canada's largest supplier of Hydroxychloroquine for the last several years, Mint is also committed to ensuring the continued supply to distributors and drugstore chains for patients who already depend on the company for this medication for its current indications." added Devin Jensen, National Sales Director of Mint Pharmaceuticals Inc.
About Mint Pharmaceuticals Inc.
Mint is a leading generic pharmaceutical manufacturer of high quality and affordable generic pharmaceutical products to the Canadian market. Canadian owned and operated company, Mint has repeatedly been recognized as one of the fastest growing pharmaceutical companies in Canada, according to IQVIA and one of the most reputable generic manufacturers in Canada by Advantage Survey. Since 2014, the company has averted 14 national drug shortages on 9 different drugs through our best in class supply chain management. In 2019, the company was recognized by Deloitte and CIBC as one of Canada's Best Managed Businesses.
SOURCE Mint Pharmaceuticals